Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 34 - Tom Graney News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tom Graney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tom Graney Today - Breaking & Trending Today
Summer camp in Delaware County cancels first two weeks following COVID-19 outbreak
New Life Ranch Flint Valley cancels first two weeks of summer camp.
Source: msn.com
Oxurion NV: OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)
THR-687 is a potent pan-RGD integrin antagonistholding potential as next generation first line therapy for DME Leuven, BE, Boston, MA, US - June 10, 2021 - 07.00 AM CET - Oxurion
Source: finanznachrichten.de
Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV Business and Financial Update – FY 2020
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020 The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO. At the end of December 2020, Oxurion had cash, cash equiva...
Source: investegate.co.uk
Oxurion NV Business and Financial Update – FY 2020
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020 The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO. At the end of December 2020, Oxurion had cash, cash equiva...
Source: globenewswire.com